Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute
Brooks Announces GENEWIZ Selected as Genome Characterization Center by the National Cancer Institute CHELMSFORD, Mass., Jan. 12, 2021 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that GENEWIZ, the Company’s genomics analysis business, has been awarded one of six Genome Characterization Center Indefinite Delivery Indefinite Quantity (IDIQ) contracts from the National Cancer Institute (NCI). The NCI,... Read more